Document Detail

Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.
MedLine Citation:
PMID:  22368692     Owner:  NLM     Status:  Publisher    
Lung cancer is the leading cause of all cancer deaths in the US. The international scientific and clinical community has made significant advances toward understanding specific molecular mechanisms underlying lung carcinogenesis; however, despite these insights and advances in surgery and chemoradiotherapy, the prognosis for non-small-cell lung cancer (NSCLC) remains poor. Nonetheless, significant effort is being focused on advancing translational research evaluating the efficacy of novel targeted therapeutic strategies for lung cancer. Illustrative examples of this include antagonists of the epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib, and a diverse assortment of anti-angiogenic compounds targeting growth factors and/or their receptors that regulate tumor-associated angiogenic programs. In addition, with the increased awareness of the significant role chronically activated leukocytes play as potentiators of solid-tumor development, the role of innate and adaptive immune cells as regulators of lung carcinogenesis is being examined. While some of these studies are examining how novel therapeutic strategies may enhance the efficacy of lung cancer vaccines, others are evaluating the intrinsic characteristics of the immune response to lung cancer in order to identify rate-limiting molecular and/or cellular programs to target with novel anticancer therapeutics. In this article, we explore important aspects of the immune system and its role in regulating normal respiratory homeostasis compared with the immune response accompanying development of lung cancer. These hallmarks are then discussed in the context of recent efforts to develop lung cancer vaccines, where we have highlighted important concepts that must be taken into consideration for future development of novel therapeutic strategies and clinical trials assessing their efficacy.
Adam Yagui-Beltrán; Lisa M Coussens; David M Jablons
Publication Detail:
Journal Detail:
Title:  US oncology     Volume:  58     ISSN:  1758-4035     ISO Abbreviation:  -     Publication Date:  2009  
Date Detail:
Created Date:  2012-2-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101553257     Medline TA:  US Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  40-48     Citation Subset:  -    
Post-doctoral Fellow, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
R01 CA132566-04//NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unusual recurrence of small cell lung carcinoma.
Next Document:  Nuclear Division Index may Predict Neoplastic Colorectal Lesions.